SG/CALL/REGENERON PHARMACEUTICALS/1150/0.01/21.03.25 Share Price

Warrant

DE000SW7LB73

Market Closed - Boerse Frankfurt Warrants 01:15:06 24/05/2024 am IST
0.46 EUR -2.13% Intraday chart for SG/CALL/REGENERON PHARMACEUTICALS/1150/0.01/21.03.25
Current month+51.61%
1 month+34.29%
Date Price Change
23/24/23 0.47 0.00%
22/24/22 0.47 -4.08%
21/24/21 0.49 +4.26%
20/24/20 0.47 +2.17%
17/24/17 0.46 +6.98%

Real-time Boerse Frankfurt Warrants

Last update May 24, 2024 at 01:15 am IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SW7LB7
ISINDE000SW7LB73
Date issued 12/03/2024
Strike 1,150 $
Maturity 21/03/2025 (302 Days)
Parity 100 : 1
Emission price 0.66
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.66
Lowest since issue 0.26
Delta0.36x
Omega 7.119
Premium22.29x
Gearing19.94x
Moneyness 0.8527
Difference Strike 169.4 $
Difference Strike %+14.73%
Spread 0.01
Spread %2.17%
Theoretical value 0.4550
Implied Volatility 25.76 %
Total Loss Probability 72.59 %
Intrinsic value 0.000000
Present value 0.4550
Break even 1,199.18 €
Theta-0.01x
Vega0.03x
Rho0.02x

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
980.6 USD
Average target price
1,042 USD
Spread / Average Target
+6.26%
Consensus